| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1018 |
| Guru Rank Value : 0.1 |
| Guru Occurances : 4 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
11,732 |
293,417 |
| Total Sell Value |
$0 |
$0 |
$809,527 |
$24,984,271 |
| Total People Sold |
0 |
0 |
3 |
8 |
| Total Sell Transactions |
0 |
0 |
5 |
28 |
| End Date |
2025-09-07 |
2025-06-06 |
2024-12-06 |
2023-12-07 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hardy Alexander |
Chief Executive Officer |
• • – |
2025-12-01 |
4 |
D |
$55.03 |
$911,847 |
D/D |
(16,570) |
159,388 |
|
- |
|
| Friberg Gregory R |
EVP, Chief R&D Officer |
• – – |
2025-09-30 |
4 |
D |
$54.16 |
$178,945 |
D/D |
(3,304) |
43,506 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2025-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
7,000 |
|
- |
|
| Countouriotis Athena |
Director |
– • – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,650 |
13,550 |
|
- |
|
| Hubbard Cristin |
EVP, Chief Commercial Officer |
• – – |
2025-05-20 |
4 |
D |
$59.93 |
$129,149 |
D/D |
(2,155) |
30,545 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,650 |
127,426 |
|
- |
|
| Enyedy Mark J |
Director |
– • – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,650 |
13,550 |
|
- |
|
| Walbert Timothy P |
Director |
– • – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,650 |
9,780 |
|
- |
|
| Bodem Barbara W. |
Director |
– • – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,650 |
13,555 |
|
- |
|
| Hombach Robert J. |
Director |
– • – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,650 |
41,870 |
|
- |
|
| Dere Willard H |
Director |
– • – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,650 |
38,950 |
|
- |
|
| Anderson Elizabeth M |
Director |
– • – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,650 |
34,450 |
|
- |
|
| Ho Maykin |
Director |
– • – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,650 |
28,010 |
|
- |
|
| Burkhart Erin |
GVP, Chief Accounting Officer |
• – – |
2025-05-20 |
4 |
AS |
$59.31 |
$105,928 |
D/D |
(1,786) |
14,173 |
|
- |
|
| Burkhart Erin |
GVP, Chief Accounting Officer |
• – – |
2025-05-19 |
4 |
D |
$59.27 |
$59,033 |
D/D |
(996) |
15,959 |
|
- |
|
| Hubbard Cristin |
EVP, Chief Commercial Officer |
• – – |
2025-05-02 |
4 |
AS |
$64.92 |
$17,723 |
D/D |
(273) |
32,700 |
|
- |
|
| Hardy Alexander |
Chief Executive Officer |
• • – |
2025-04-30 |
4 |
A |
$54.14 |
$20,301 |
D/D |
375 |
175,958 |
|
- |
|
| Hubbard Cristin |
EVP, Chief Commercial Officer |
• – – |
2025-04-30 |
4 |
A |
$54.14 |
$14,779 |
D/D |
273 |
32,973 |
|
- |
|
| Burkhart Erin |
GVP, Chief Accounting Officer |
• – – |
2025-03-19 |
4 |
AS |
$71.52 |
$92,618 |
D/D |
(1,295) |
16,955 |
|
- |
|
| Guyer Charles Greg |
EVP, Chief Technical Officer |
• – – |
2025-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
13,310 |
80,838 |
|
- |
|
| Burkhart Erin |
GVP, Chief Accounting Officer |
• – – |
2025-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,970 |
18,252 |
|
- |
|
| Friberg Gregory R |
EVP, Chief R&D Officer |
• – – |
2025-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
17,750 |
46,810 |
|
- |
|
| Hubbard Cristin |
EVP, Chief Commercial Officer |
• – – |
2025-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
13,310 |
32,700 |
|
- |
|
| Hardy Alexander |
Chief Executive Officer |
• • – |
2025-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
44,360 |
175,583 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2025-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
16,640 |
99,781 |
|
- |
|
1143 Records found
|
|
Page 1 of 46 |
|
|
1.44 (1.6%) 
